Vigil Neuroscience Inc (VIGL)

Jun 4, 2025, 7:00 AM EDT - 1 day ago

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

May 22, 2025, 6:43 PM EDT - 13 days ago

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

SNY

May 21, 2025, 7:59 PM EDT - 14 days ago

Sanofi to Buy Vigil Neuroscience for About $470 Million

SNY

May 21, 2025, 7:30 PM EDT - 14 days ago

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

SNY

May 21, 2025, 7:29 PM EDT - 14 days ago

Sanofi to acquire Vigil Neuroscience in $470 million deal

SNY

May 21, 2025, 7:15 PM EDT - 14 days ago

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline

SNY

May 7, 2025, 7:00 AM EDT - 4 weeks ago

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Apr 2, 2025, 7:00 AM EDT - 2 months ago

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Mar 13, 2025, 7:00 AM EDT - 3 months ago

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Mar 11, 2025, 7:00 AM EDT - 3 months ago

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Jan 30, 2025, 7:00 AM EST - 4 months ago

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 23, 2025, 11:33 AM EST - 4 months ago

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Jan 23, 2025, 7:00 AM EST - 4 months ago

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease

Jan 8, 2025, 4:05 PM EST - 5 months ago

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

Sep 17, 2024, 7:00 AM EDT - 9 months ago

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

Sep 16, 2024, 4:05 PM EDT - 9 months ago

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

Aug 29, 2024, 7:00 AM EDT - 10 months ago

Vigil Neuroscience to Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 10 months ago

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 24, 2024, 7:00 AM EDT - 11 months ago

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Jul 18, 2024, 4:05 PM EDT - 11 months ago

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

Jul 18, 2024, 7:00 AM EDT - 11 months ago

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Jun 27, 2024, 2:00 AM EDT - 1 year ago

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

Jun 26, 2024, 1:00 AM EDT - 1 year ago

Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

May 30, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present in Upcoming June Investor Conferences

May 8, 2024, 7:40 AM EDT - 1 year ago

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

May 7, 2024, 4:05 PM EDT - 1 year ago

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

Mar 26, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 20, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Mar 13, 2024, 7:05 AM EDT - 1 year ago

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Mar 12, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

Mar 6, 2024, 4:25 PM EST - 1 year ago

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Feb 29, 2024, 4:05 PM EST - 1 year ago

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Feb 7, 2024, 4:05 PM EST - 1 year ago

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 3, 2024, 4:30 PM EST - 1 year ago

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

Nov 22, 2023, 4:05 PM EST - 1 year ago

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

Nov 20, 2023, 7:34 PM EST - 1 year ago

Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway

Nov 16, 2023, 4:05 PM EST - 1 year ago

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

Nov 7, 2023, 7:05 AM EST - 1 year ago

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 17, 2023, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease

Oct 5, 2023, 4:01 PM EDT - 1 year ago

Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Sep 26, 2023, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

Sep 18, 2023, 2:38 PM EDT - 1 year ago

Vigil Neuroscience: Interesting Early Data, Wait For Phase 2

Sep 11, 2023, 12:00 PM EDT - 1 year ago

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

Sep 8, 2023, 4:05 PM EDT - 1 year ago

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

Sep 8, 2023, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference